[{"from": "human", "value": "What can you tell me about this molecule? [C][O][C][=C][Branch2][Ring2][=Branch1][C][=C][C][=C][N][C][C][N][Ring1][Branch1][C][=Branch1][P][=N][C][=Branch1][C][=O][C][=C][N][=C][Branch1][Branch1][N][=C][Ring1][=Branch1][N][N][=C][Ring2][Ring1][Ring1][Ring2][Ring1][#Branch1][O][C][C][C][N][C][C][O][C][C][Ring1][=Branch1]"}, {"from": "gpt", "value": "The molecule is a selective pan-Class I phosphoinositide 3-kinase (PI3K/Phosphatidylinositol-4,5-bisphosphate 3-kinase/phosphatidylinositide 3-kinase) inhibitor that was first developed by Bayer Healthcare Pharmaceuticals, Inc. The drug targets the enzyme that plays a role in regulating cell growth and survival. Copanlisib was granted accelerated approval on September 14, 2017 under the market name Aliqopa for the treatment of adult patients with relapsed follicular lymphoma and a treatment history of at least two prior systemic therapies. Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma that is caused by unregulated proliferation and growth of lymphocytes. The active ingredient in Aliquopa intravenous therapy is copanlisib dihydrochloride."}]